In Vivo Efficacy of the New Ketolide Telithromycin (HMR 3647) in Murine Infection Models
AUTOR(ES)
Bonnefoy, Alain
FONTE
American Society for Microbiology
RESUMO
We compared the oral antibacterial activities of telithromycin (HMR 3647), a new ketolide drug, in different infections induced in mice by Staphylococcus aureus, Streptococcus pneumoniae, streptococci, enterococci, and Haemophilus influenzae with those of various macrolides and pristinamycin. Unlike all other comparators, telithromycin displayed a high therapeutic activity, particularly in septicemia induced by erythromycin A-resistant pathogens, where the ketolide was the only active compound, displaying effective doses between 3 and 26 mg/kg of body weight. Against H. influenzae, telithromycin was the most effective compound. Telithromycin displayed bacteriostatic behavior against S. pneumoniae and H. influenzae. The ketolide was also active against thigh muscle infection induced by S. aureus. The pharmacokinetic properties of telithromycin accounted for its outstanding well-balanced oral in vivo efficacy against both gram-positive cocci, whatever their phenotype of resistance, and H. influenzae.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=90532Documentos Relacionados
- Bronchopulmonary Disposition of the Ketolide Telithromycin (HMR 3647)
- Pharmacokinetics of the New Ketolide Telithromycin (HMR 3647) Administered in Ascending Single and Multiple Doses
- Efficacy of Telithromycin (HMR 3647) against Enterococci in a Mouse Peritonitis Model
- In Vitro Activities of the Novel Ketolide Telithromycin (HMR 3647) against Erythromycin-Resistant Streptococcus Species
- In Vitro Susceptibilities of Rapidly Growing Mycobacteria to Telithromycin (HMR 3647) and Seven Other Antimicrobials
